A review of antipsychotics in the treatment of obsessive compulsive disorder

Journal of Psychopharmacology

Volumn 20, Issue 1, 2006, Pages 97-103

  Fineberg, Naomi A ^a,b   Gale, Tim M ^a,b   Sivakumaran, Thanusha ^a  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; AMISULPRIDE; ARIPIPRAZOLE; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; DESIPRAMINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PIMOZIDE; PINDOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TRYPTOPHAN; UNINDEXED DRUG;

ADD ON THERAPY; AKATHISIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DOPAMINE BRAIN LEVEL; DOPAMINE RECEPTOR BLOCKING; DROWSINESS; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXTRAPYRAMIDAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; INFORMATION RETRIEVAL; MAXIMUM TOLERATED DOSE; MEDICAL INFORMATION; META ANALYSIS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PUBLICATION; REVIEW; SCHIZOPHRENIA; SEROTONIN BRAIN LEVEL; SIDE EFFECT; SYSTEMATIC REVIEW; TIC; TITRIMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN; YALE BROWN OBSESSIVE COMPULSIVE SCALE; DRUG COMBINATION; PSYCHOLOGICAL ASPECT; TREATMENT FAILURE;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33645233540     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881105056640     Document Type: Review

References (69)

1. Ackerman D L, Greenland S (2002) Multivariate meta-analysis of controlled drug studies for obsessive compulsive disorder. J Clin Psychopharmacol 22: 309-317
2. Altschuler M (1962) Massive doses of trifluoperazine in the treatment of compulsive rituals. Am J Psychiat 119: 367-368
3. Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002) Quetiapine augmentation in patients with treatment-resistant obsessive compulsive disorder. A single blind, placebo-controlled study. Int Clin Psychopharmacol 17: 115-119
4. Barr L C, Goodman W K, Anand A, McDougle C J, Price L H (1997) Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiat 154: 1293-1295
5. Barr L C, Goodman W K, McDougle C J, Delgado P L, Heninger G R, Charney D S, Price L H (1994) Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiat 51: 309-317
6. Bejerot S, Bodlund O (1998) Response to high doses of citalopram in treatment-resistant obsessive compulsive disorder. Acta Psychopharmacol Scandinavia 98: 423-424
7. Blier P, Bergeron R (1996) Sequential administration of augmentation strategies in treatment resistant obsessive compulsive disorder: preliminary findings. Int Clin Psychopharmacol 11: 37-44
8. Bogan A M, Koran L M, Chuong H V, Vapnik T, Bystritsky A (2005) Quetiapine augmentation in obsessive compulsive disorder resistant to serotonin reuptake inhibitors: an open label study. J Clin Psychiat 66: 73-79
9. Bogetto F, Bellino S, Vaschetto P, Ziero S (2000) Olanzapine augmentation of fluvoxamine-refractory obsessive compulsive disorder (OCD): a twelve-week open trial. Psychiat Res 95: 91-98
10. Buchsbaum M S, Hollander E, Pallanti S, Baldini-Rossi N, Platholi J, Bloom R, Sood E (2002) Risperidone in Refractory OCD: Positron Emission Tomography Imaging. 42nd NCDEU Meeting, Boca Raton
11. Bymaster F P, Katner J S, Nelson D L, Hemrick-Luecke S K, Threlkeld P G, Heilingstein J H, Morin S M, Gehlert D R, Perry K W (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5): 699-711
12. Byerly M J, Goodman W K, Christenen R (1996) High doses of sertraline for treatment-resistant obsessive compulsive disorder. Am J Psychiat 153: 1232-1233
13. Bystritsky A, Ackerman D L, Rosen R, Vapnik T, Gorbis E, Maidment K M, Saxena S (2004) Augmentation of SSRI response in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiat 65: 565-568
14. Carey P D, Vythilingum B, Seedat S, Muller J E, van Ameringen M, Stein D J (2005) Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study: BMC Psychiat 5(1): 5
15. Connor KM, Payne V M, Gadde KM, Zhang W Davidson J R (2005) The use of aripiprazole in obsessive compulsive disorder: preliminary observations in 8 patients. J Clin Psychiat 66(1): 49-51
16. Crocq M A, Leclercq P, Guillon M S, Bailey P E (2002) Open-label olanzapine in obsessive compulsive disorder refractory to antidepressant treatment. Eur Psychiat 17: 296-297
17. D'Amico G, Cedro C, Muscatello M R, Pandolfo G, Di Rosa A E, Zoccali R, La Torre D, D'Amigo C, Spina E (2003) Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Progress in Neuro-psychopharmacology and Biological Psychiat 27: 619-623
18. Dannon P N, Sasson Y, Hirschmann S, Iancu I, Grunhaus L J, Zohar J (2000) Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 10: 165-169
19. Denys D, de Geus F, van Megen HJGM, Westenberg HGM (2004a) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psych 65: 1040-1048
20. Denys D, Klompmakers A A, Westenberg H G (2004c) Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) 176(2): 195-203
21. Denys D, van der Wee N, Janssen J, De Geus F, Westenberg H G (2004b) Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiat 55: 1041-1045
22. Denys D, van Megen H, Westenberg H (2002) Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment refractory obsessive compulsive disorder: an open label study. J Clin Psychiat 63: 700-703
23. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L (2005) Low-dose risperidone augmentation of fluvoxamine treatment for obsessive compulsive disorder: a double-blind placebo-controlled study. Eur Neuropsychopharmacol 15(1): 69-74
24. Fallon B A, Liebowitz M R, Campeas R, Schneier F R, Marshall R, Davies S, Goetz D, Klein D F (1998) Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiat 55: 918-924
25. Fineberg N A, Sivakumaran T, Roberts A, Gale T (2005) Adding quetiapine to SRI in treatment-resistant obsessive compulsive disorder: a randomised controlled treatment study. Int Clin Psychopharmacol 20: 223-226
26. Francobandiera G (2001) Olanzapine augmentation of serotonin uptake inhibitors in obsessive compulsive disorder: an open study. Can J Psychiat 46: 356-358
27. Geller D A, Biederman J, Evelyn Stewart S, Mullin B, Martin A, Spencer T, Faraone S V (2003) Which SSRI? A meta-analysis of pharmacotherapy trials in paediatric obsessive compulsive disorder. Am J Psychiat 160: 1919-1928
28. Grady T A, Pigott T A, L'Heureux F, Hill J L, Berntein S E, Murphy D L (1993) Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiat 150: 819-821
29. Hollander E, Rossi N B, Sood E, Pallanti S (2003a) Risperidone augmentation in treatment-resistant obsessive compulsive disorder: a double-blind, placebo controlled study. Int J Neuropsychopharmacol 6: 397-401
30. Hollander E, Kaplan A, Stahl S M (2003b) A double-blind placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biological Psychiat 4: 30-34
31. Hussain M Z, Ahad A ( 1970) Treatment of obsessive compulsive neurosis. Can Med Assoc J 103: 648
32. Koran L M, Ringold A L, Elliott M A (2000) Olanzapine augmentation for treatment-resistant obsessive compulsive disorder. J Clin Psychiat 61: 514-517
33. Maina G, Albert U, Ziero S, Bogetto F (2003) Antipsychotic augmentation for treatment-resistant obsessive compulsive disorder: What if antipsychotic is discontinued? Int Clin Psychopharmacol 18: 23-28
34. March J S, Frances A, Kahn D A, Carpenter D (1997) The Expert Consensus Guideline Series: treatment of obsessive-compulsive disorder. J Clin Psychiat 58 (suppl.): 1-72
35. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacol 28: 402-412
36. Mataix-Cols D, Rauch S, Manzo P A, Jenike M A, Baer L (1999) Use of factor-analysed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive compulsive disorder. Am J Psychiat 156: 1409-1416
37. McDougle C J, Barr L C, Goodman W K, Pelton G H, Aronson S C, Anand A, Price L H (1995b) Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiat 152: 423-429
38. McDougle C J, Epperson C N, Pelton G H, Wasylink S, Price L H (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiat 57: 794-801
39. McDougle C J, Fleischmann R L, Epperson C N, Wayslink S, Leckmann J F, Price L H (1995a) Risperidone addition in fluvoxamine refractory obsessive compulsive disorder: three cases. J Clin Psychiat 56: 526-528
40. McDougle C J, Goodman W K, Leckman J F, Holzer J C, Barr L C, McCance-Katz E (1993) Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiat 750: 647-649
41. McDougle C J, Goodman W K, Leckman J F, Lee N C, Heninger G R, Price L H (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiat 51: 302-308
42. McDougle C J, Goodman W K, Price L H, Delgado P L, Krystal J H, Charney D S, Heninger G R (1990) Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiat 147: 652-654
43. McDougle C J, Price L H, Goodman W K, Charney D S, Heninger G R (1991) A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. J Clin Psychopharmacol 11: 175-184
44. McDougle C J, Walsh K H (2001) Treatment for refractory OCD. In: Fineberg N A, Marazitti D, Stein D (eds), Obsessive Compulsive Disorder: A Practical Guide. Martin Dunitz, London
45. Metin O, Yaziki K, Tot S, Yazici A E (2003) Amisulpride augmentation in treatment-resistant obsessive compulsive disorder: an open trial. Hum Psychopharmacol 18: 463-467
46. Mohr N, Vythilingum B, Emsley R A, Stein D J (2002) Quetiapine augmentation of serotonin reuptake inhibitors in obsessive compulsive disorder. Int Clin Psychopharmacol 17: 37-40
47. Mundo E, Bareggi S R, Pirola R, Bellodi L (1999) Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: Is gender a predictive variable? Biol Psychiat 45: 290-294
48. Mundo E, Guglielmo E, Bellodi L (1998) Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine; a double-blind, placebo-controlled study. Int Clin Psychopharmacol 13: 219-224
49. O'Regan J B (1970) Treatment of obsessive-compulsive neurosis. Can Med Assoc J 103: 650-651
50. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar and the International Treatment-Refractory OCD Consortium (2002a) Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5: 181-191
51. Pallanti S, Quercioli L, Bruscoli M (2004) Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiat 65(10):1394-1399
52. Pallanti S, Quercioli L, Koran L M (2002b) Citalopram infusions in resistant obsessive compulsive disorder: an open trial. J Clin Psychiat 63: 796-801
53. Pallanti S, Quercioli L, Paiva R S, Koran L M (1999) Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiat 14: 101-106
54. Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano G B (2000) Risperidone augmentation in refractory obsessive compulsive disorder: an open-label study. Int Clin Psychopharmacol 15: 297-301
55. Pigott T A, L'Heureux F, Hill J L, Bihari K, Bernstein S E, Murphy D L (1992a) A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive compulsive disorder. J Clin Psychopharmacol 12: 11-18
56. Pigott T A, L'Heureux F, Rubinstein C F, Hill J L, Murphy D L (1992b) A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. New Research Abstracts NR 144 presented at the 145th Annual Meeting of the American Psychiatric Association, Washington, DC, USA
57. Pigott T A, Pato M T, L'Heureux F, Hill J L, Grover G N, Bernstein S E, Murphy D L (1991) A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive compulsive disorder. J Clin Psychopharmacol 11: 242-248
58. Poyurovsky M, Koran L (2005) Obsessive compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. J Psychiatr Res 39(4): 399-408
59. Rivers-Bulkeley N, Hollender M H (1982) Successful treatment of obsessive-compulsive disorder with loxapine. Am J Psychiat 139: 1345-1346
60. Sareen J, Kirshner A, Lander M, Kjeniested K D, Eleff M K, Reiss J P (2004) Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder? A systematic review. J Affective Disorders 82: 167-174
61. Saxena S, Brody A L, Ho M L, Zohrabi N, Maidment K M, Baxter L (2003) Differential brain metabolic predictors of response to paroxetine in obsessive compulsive disorder versus major depression. Am J Psychiat 160: 522-532
62. Saxena S, Wang D, Bystritsky A, Baxter Jr L R (1996) Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiat 57: 303-306
63. Sevincok L, Topuz A (2003) Lack of efficacy of low dose quetiapine addition in refractory obsessive compulsive disorder. J Clin Psychopharmacol 23: 448-450
64. Shapira N A, Ward H E, Mandoki M, Murphy T K, Yang M C, Blier P, Goodman W K (2004) A double-blind placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive compulsive disorder. Biol Psychiat 55: 553-563
65. Stein D J, Bouwer C, Hawkridge S, Emsley R A (1997) Risperidone augmentation of serotonin reuptake inhibitors in obsessive compulsive and related disorders. J Clin Psychiat 58: 119-122
66. Stein D, Montgomery S A, Kasper S, Tanghoj P (2001) Predictors of response to pharmacotherapy with citalopram in obsessive compulsive disorder. Int Clin Psychopharmacol 16: 357-361
67. Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C (1996) Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data. J Clin Psychiat 57: 257-264
68. Trethowan W H, Scott P A (1955) Chlorpromazine in obsessive-compulsive and allied disorders. Lancet 268: 781-785
69. Weiss E L, Potenza M N, McDougle C J, Epperson C N (1999) Olanzapine addition in obsessive compulsive disorder refractory to selective serotonin reuptake inhibitors; an open-label case series. J Clin Psychiat 60: 524-527